Our research at the Conference on Retroviruses and Opportunistic Infections (CROI) 2024
29 Feb 2024
Since 1993, CROI has provided a forum for scientists to share and evaluate their research into the biology and epidemiology of human retroviruses, including HIV, and associated diseases. The conference combines basic science with clinical investigation. Over the years, CROI has showcased many important discoveries, accelerating the progress of HIV and AIDS research.
Next week, researchers from the MRC Clinical Trials Unit at UCL and our collaborators from partner institutions will travel to Denver, USA to present the latest research from our HIV trials, including START, ODYSSEY and D3.
Details of the presentations are summarised below. All times are in MST.
| Day | Time | Session | Title | Presenter |
| Tuesday 5 March |
2:30 - 4:00 PM | Poster session: Pharmacokinetics, dosing and safety of antiretrovirals for infants, children, and adolescents |
Poster 00946 - Pharmacokinetics of once-daily DTG/3TC FDC in children living with HIV: D3/PENTA21 sub-study |
Lisanne Bevers |
| Wednesday 6 March | 10:00 AM - 12:00 PM | HIV across the life continuum: Pregnant people, infants, children and adolescents |
ODYSSEY 192-week follow-up evidences superior efficacy of DTG for children on first/second-line ART |
Hilda Mujuru |
| 2:30 - 4:00 PM | Poster session: Aging and frailty |
Poster 00837 - Excess inflammation associated with AIDS and non-AIDS complications in adults on ART |
Kanal Singh |
Further information: